The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | Enhancing the efficacy of immunotherapy in lung cancer
Wolf-Hervé Fridman, MD, PhD, of Inserm, Paris, France, addresses the novel therapeutic targets that could help overcome resistance to immunotherapy in lung cancer. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Fridman discusses the new perspectives on improving immunotherapy efficacy in lung cancer treatment through modulating regulatory T-cells, cytotoxic T-cells, macrophages, and the microbiota.
